NBTX
Nanobiotix S.A.
NASDAQ · Healthcare · Biotechnology · FR
$38.80
−3.00%Institutional positioning
13F filings over the trailing two quarters
New 3Increased 2Reduced 7Sold out 15
| Filer | Action | Shares | Filed |
|---|---|---|---|
| JOHNSON & JOHNSON | Reduced | 5,623,816 | May 13, 2026 |
| JOHNSON & JOHNSON | Unchanged | 5,623,816 | Mar 18, 2026 |
| MORGAN STANLEY | Reduced | 36,274 | May 15, 2026 |
| OPTIVER HOLDING B.V. | Reduced | 13,501 | Jun 2, 2026 |
| MARSHALL WACE, LLP | Reduced | 9,239 | May 15, 2026 |
| CITADEL ADVISORS LLC | New Position | 6,042 | Sep 2, 2026 |
| UBS GROUP AG | Increased | 5,557 | May 5, 2026 |
| BNP PARIBAS ARBITRAGE, SNC | Reduced | 3,559 | May 12, 2026 |
| RHUMBLINE ADVISERS | Reduced | 2,281 | May 12, 2026 |
| ROYAL BANK OF CANADA | Reduced | 1,825 | May 15, 2026 |
| GAMMA INVESTING LLC | Increased | 828 | Apr 6, 2026 |
| EVERSOURCE WEALTH ADVISORS, LLC | Unchanged | 514 | May 18, 2026 |
| ADVISOR GROUP HOLDINGS, INC. | Unchanged | 500 | May 15, 2026 |
| WELLS FARGO & COMPANY/MN | Unchanged | 200 | Jul 8, 2026 |
| NATIONAL BANK OF CANADA /FI/ | Unchanged | 13 | May 15, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings